PMID: 7002567Nov 1, 1980

Time-course of the anti-hypertensive action of atenolol: comparison of response to first dose and to maintained oral administration

European Journal of Clinical Pharmacology
G LeonettiA Zanchetti

Abstract

To show whether repeated administration of atenolol for several days would influence its pharmacokinetic parameters and the extent and duration of the pharmacologic responses, the plasma level of atenolol and changes in heart rate, blood pressure and plasma renin activity were measured in 12 hypertensive patients at various times of day (9 a. m., 12 noon, 3 p. m. and 7 p. m.) after oral administration of the first dose of atenolol 100 mg, again during the 7th and 14th days of continued once-daily administration of the same dose, and finally during the three days following withdrawal of the drug. The peak plasma concentration of atenolol (about 600 ng/ml) was found 3 h after administration of the first dose, and measurable amounts (50-70 ng/ml) were found after 24 h. None of the pharmacokinetic characteristics were changed by administration of a single daily dose for two weeks. After withdrawal of the drug, detectable amounts of atenolol were found in plasma for at least 48 h. The first dose of atenolol caused prompt (3 h) and prolonged (up to 24 h) lowering of supine and standing systolic and diastolic blood pressures, slowing of supine and standing heart rate, reduction of the blood pressure and heart rate responses to dynamic...Continue Reading

References

Nov 1, 1976·Clinical Pharmacology and Therapeutics·H C BrownR G Shanks
Jun 1, 1975·The Journal of Pharmacy and Pharmacology·B Scales, P B Copsey
Jun 1, 1977·Clinical Pharmacology and Therapeutics·A AmeryT Reybrouck
Nov 1, 1977·Postgraduate Medical Journal·C M CastledenC F George
Jan 1, 1977·Current Medical Research and Opinion·N K GostickN P Barmer
Nov 27, 1978·European Journal of Clinical Pharmacology·A P Douglas-JonesA Lee
Jan 27, 1979·British Medical Journal·M W CraigE B Raftery
Nov 14, 1977·European Journal of Clinical Pharmacology·J SassardP Zech
May 17, 1978·European Journal of Clinical Pharmacology·J D FitzgeraldJ McAinsh
Apr 24, 1976·British Medical Journal·A P Douglas-Jones, J M Cruickshank
Jul 1, 1975·Circulation·A S Nies, D G Shand
Apr 1, 1975·British Journal of Clinical Pharmacology·G E MarlinP Turner
May 2, 1974·The New England Journal of Medicine·H Aberg
Feb 1, 1972·The Journal of Clinical Endocrinology and Metabolism·A M Michelakis, R G McAllister

Citations

Aug 8, 2007·Scandinavian Cardiovascular Journal : SCJ·Bengt AbladTherese Edström
Jan 1, 1985·Clinical and Experimental Hypertension. Part A, Theory and Practice·M A van BaakJ F Smits
Jul 20, 2016·Journal of Pharmacological and Toxicological Methods·Patricia N BanforPhilip D Zocharski
Apr 22, 1991·The American Journal of Cardiology·L Hansson
Jan 1, 1993·Journal of the American Psychoanalytic Association·C F Settlage

Related Concepts

Tenormin
Diastolic Blood Pressure
Pulse Rate
Hypertensive Disease
Propanolamines
Preprorenin

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Synthetic Genetic Array Analysis

Synthetic genetic arrays allow the systematic examination of genetic interactions. Here is the latest research focusing on synthetic genetic arrays and their analyses.

Congenital Hyperinsulinism

Congenital hyperinsulinism is caused by genetic mutations resulting in excess insulin secretion from beta cells of the pancreas. Here is the latest research.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Epigenetic Memory

Epigenetic memory refers to the heritable genetic changes that are not explained by the DNA sequence. Find the latest research on epigenetic memory here.

Cell Atlas of the Human Eye

Constructing a cell atlas of the human eye will require transcriptomic and histologic analysis over the lifespan. This understanding will aid in the study of development and disease. Find the latest research pertaining to the Cell Atlas of the Human Eye here.

Femoral Neoplasms

Femoral Neoplasms are bone tumors that arise in the femur. Discover the latest research on femoral neoplasms here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.